Medicine composition used for treating diabetes mellitus

A composition and technology for diabetes, applied in drug combinations, metabolic diseases, pharmaceutical formulations, etc., to achieve the effects of improving insulin resistance, protecting islet cell function, and lowering cholesterol

Inactive Publication Date: 2018-06-15

王桂芬

3 Cites 0 Cited by

AI-Extracted Technical Summary

Problems solved by technology

It can be used alone or in combination with sulfonylureas or insulin for the treatment of obese diabetes, so it is widely used clinically. The common adverse reactions of metformi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine

Abstract

The invention relates to a medicine composition used for treating diabetes mellitus. The medicine composition is prepared from, by weight, 30-35 parts of herba lycopi extract, 30-35 parts of rhizoma polygonati, 15-20 parts of radix ginseng, 95-105 parts of bitter gourds, 60-70 parts of stanuntonia chinensis, 30-35 parts of chayote and 45-55 parts of melbine. When the medicine composition is applied to a patient for improving type 2 diabetes mellitus insulin resistance and treating poor Western medicine control and improving and reversing abnormal glucose tolerance of an early-state patient inclinical observation, the effect is obviously superior to that of the patient who purely uses melbine, the composition is reasonable, the compatibility is moderate, used drugs are precise and specific, when many drugs are combined, the synergistic effect can be better given play to, the insulin resistance is improved, islet cells are protected, obesity can also be improved, and adverse reactions can be reduced.

Application Domain

Organic active ingredientsMetabolism disorder +1

Technology Topic

MetforminDrug +8

Image

Examples

Experimental program(1)

Example Embodiment

[0039] Example: The pharmaceutical composition consists of the following raw materials:

[0040] Eupatorium extract 330, Polygonatum 330g, ginseng 170g, bitter melon 990g, wild papaya 650g, chayote 330g and metformin 500g.

[0041] (1) Dry and crush ginseng, rhizome, wild papaya, bitter gourd and chayote at 45~50℃ to 120 mesh fine powder;

[0042] (2) Take Eupatorium, add 4-6 times the amount of water each time, decoct twice, the first time is 1.5-2 hours, the second time is 0.5-1 hour, combine the two decoctions, filter, and concentrate the filtrate When the temperature reaches 80~85℃, the relative density 1.08~1.10 of the clear paste, add ethanol to make the clear paste contain 70% alcohol, stand for 24 hours, recover the ethanol, and concentrate to the relative density 1.30~1.32 at 50~55℃ The cleansing ointment, dry, get the adenophora extract, and then crush it into 120 mesh fine powder;

[0043] (3). Mix metformin with the fine powder prepared in (1) and (2) according to the stated ratio, add proper amount of sucrose and soluble starch, granulate with ethanol, dry and pack into bags, making a total of 1,000 bags.

[0044] (1) Clinical observation of 40 cases of type 2 diabetes with the pharmaceutical composition prepared in the embodiment:

[0045] 1. Materials and methods:

[0046] Research objects: 80 cases were selected that met the 1999 WHO diagnostic criteria and met the following conditions: ①The initial diagnosis or diagnosis did not exceed half a year without treatment, and fasting blood glucose ≥ 11.1mmol/L, the average age was (55.12±5.85) years, and the course of the disease The average is (26.13±3.96) months. ②Exclusion criteria: Patients with type 1 diabetes, patients with severe heart, liver, kidney dysfunction and acute infection, women during lactation and pregnancy, under 18 years of age and> 65-year-old patient.

[0047] Treatment method: 80 eligible patients were randomly divided into two groups. ①Control group: On the basis of diabetes health education and diet therapy, metformin was used in combination, 0.5g each time, 3 times a day. ②Treatment group: on the basis of diabetes health knowledge education and diet therapy for patients, the pharmaceutical composition of the embodiment is applied together, 1 bag each time, each bag contains Chinese medicine components and 0.5g of metformin, 3 times a day, with meals oral. The two groups of patients had no statistically significant differences in gender, age, body mass index, glycosylated hemoglobin, fasting blood glucose, and approximate time to onset distribution.

[0048] Observation indicators: ①Safety indicators: such as blood routine, stool routine, liver function, renal function test, electrocardiogram, etc.; ②curative index: body mass index before and after treatment, blood glucose reaching standard time; ③Laboratory examination: glycosylated hemoglobin after treatment ( HbAlc), glucose tolerance test, fasting insulin (FINS), insulin sensitivity index (ISI) and insulin resistance index (IR), total cholesterol (TC) and triglycerides (TG). ③Gastrointestinal adverse reaction indicators: such as nausea, vomiting, abdominal distension, abdominal pain, etc.

[0049] Statistical method: Use SPSS17.0 for statistical analysis of data. The measurement data adopts t test (expressed as mean±standard deviation); the classification data adopts χ 2 In the test, P≤0.05 is regarded as statistically significant, and P≤0.01 is regarded as highly statistically significant.

[0050] 2. Clinical efficacy results:

[0051] There was no significant difference in body mass index before and after treatment (P>0.05).

[0052] Time to reach the target blood glucose: The treatment was significantly shorter than that of the control group (P<0.05).

[0053] Table 1: Results of the blood glucose standard time (days) of the two groups of patients (X±s)

[0054]

[0055] Glycated hemoglobin (HbAlc): The treatment group was lower than the control group, and the results were significantly different (P<0.01).

[0056] Table 2: HbAlc (%) results of the two groups of patients before and after treatment (X±s)

[0057]

[0058] Glucose tolerance test: The treatment group was significantly lower than the control group on an empty stomach and 2h after a meal (P<0.05).

[0059] Table 3: Glucose tolerance test (mmol/l) results of the two groups of patients before and after treatment (X±s)

[0060]

[0061] Fasting insulin (FINS): There is a significant difference between the treatment group and the control group (P<0.05).

[0062] Table 4: FINS (mU/l) results of the two groups of patients before and after treatment (X±s)

[0063]

[0064] Insulin Sensitivity Index (ISI) and Insulin Resistance Index (IR): There is a significant difference between the treatment group and the control group (P<0.05).

[0065] Table 5: Results of ISI and IR before and after treatment in the two groups (X±s)

[0066]

[0067] Total cholesterol (TC) and triglycerides (TG): There are significant differences between the treatment group and the control group before and after treatment (P>0.05), and there is no significant difference between the two groups (P>0.05).

[0068] Table 6: TG (mmol/l) and TC (mmol/l) results of the two groups of patients before and after treatment (X±s)

[0069]

[0070] Results of gastrointestinal adverse reactions:

[0071] The adverse reaction of gastrointestinal tract in the control group was significantly lower than that in the treatment group (P<0.05).

[0072] Table 7: Results of gastrointestinal adverse reactions before and after treatment in the two groups

[0073]

[0074] 3. Conclusion:

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine

Login to view more

PUM

Description & Claims & Application Information

We can also present the details of the Description, Claims and Application information to help users get a comprehensive understanding of the technical details of the patent, such as background art, summary of invention, brief description of drawings, description of embodiments, and other original content. On the other hand, users can also determine the specific scope of protection of the technology through the list of claims; as well as understand the changes in the life cycle of the technology with the presentation of the patent timeline. Login to view more.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine

Login to view more

Classification and recommendation of technical efficacy words

Increase insulin sensitivity
Improve glucose tolerance

Medicine composition used for treating diabetes mellitus

A composition and technology for diabetes, applied in drug combinations, metabolic diseases, pharmaceutical formulations, etc., to achieve the effects of improving insulin resistance, protecting islet cell function, and lowering cholesterol

AI-Extracted Technical Summary

Problems solved by technology

Abstract

Image

Examples

Example Embodiment

PUM

Description & Claims & Application Information

Similar technology patents

Solid beverage for regulating blood sugar

Application of human Nectin-2 protein

Methods of Improving Glucose Tolerance, Hair Regrowth, and Bio-Availability

Method for processing hypoglycemic solid beverage or lozenge from grapefruits and cyclocarya paliurus

Novel peptides and uses thereof in therapeutic methods

Classification and recommendation of technical efficacy words

Kinase inhibitors for the treatment of diabetes and obesity

Ppar-sparing thiazolidinediones and combinations for the treatment of diabetes mellitus and other metabolic diseases

Uses of statin compound serving as partly used medicine for curing diabetes mellitus

Product formulation of sugar-lowering capsules

Nutritional products comprising saccharide oligomers

Special sea dietary food for diabetics

Compositions and methods for the treatment of liver diseases and disorders

Fulvic acid or sodium fulvate substance with hypoglycemic function

Method for producing insect tea

Compound dendrobium officinale health care product capable of assisting in reducing blood sugar